

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Risk of pregnancy loss before 20 weeks' gestation in study participants with COVID-19

Check for updates

OBJECTIVE: Many studies have evaluated birth outcomes in patients with COVID-19, but less attention has been paid to the risk of early pregnancy loss (EPL) despite the known association of miscarriage with viral infection.¹ The current literature is limited by a small number of cases, a focus on inpatient visits, and lack of longitudinal follow-up.^{2–5} These studies have primarily been conducted in Europe and Asia, which limits generalizability to a diverse US population with unique patient characteristics. To address this evidence gap, we present data on a cohort of US women with SARS-CoV-2 infection in early pregnancy to help inform clinical practice.

STUDY DESIGN: The Pregnancy Coronavirus Outcomes Registry (PRIORITY) study is an ongoing, nationwide, prospective cohort study of pregnant people COVID-19 during pregnancy in the United States. Participants were \geq 13 years, under investigation for or had confirmed COVID-19 (defined as a positive polymerase chain reaction test for SARS-CoV-2), and were enrolled from March 2020 to October 2020. For this analysis, we selected participants who were enrolled at <14 weeks gestation and who underwent SARS-CoV-2 testing; 7 were excluded owing to a lack of longitudinal follow-up. The study was approved by the University of California, San Francisco Institutional Review Board (IRB #20-30410).

Characteristics	COVID-19 positive, n=94	COVID-19 negative, $n = 15$
Age (y), mean±SD	31.2±4.77	30.5±5.37
Race and ethnicity, n (%)		
Asian	4 (4.0)	1 (5.9)
American Indian or Alaska Native	1 (1.0)	0 (0.0)
Black or African American	2 (2.1)	2 (13.3)
Hispanic or Latina	33 (35.1)	3 (20.0)
Native Hawaiian or Pacific Islander	1 (1.1)	0 (0.0)
White	62 (66.0)	10 (66.7)
Region, n (%)		
Midwest	14 (14.9)	4 (26.7)
Northeast	31 (33.0)	1 (6.7)
South	17 (18.1)	4 (26.7)
West	29 (30.9)	6 (40.0)
Gravida, mean \pm SD	2.68±1.79	1.87±0.99
Parity, mean \pm SD	1.02±1.36	0.467±0.64
Body mass index (kg/m ²), mean \pm SD	26.8±6.45	24±4.22
Gestational age at enrollment (wk), mean \pm SD	9.76±2.84	9.83±3.24
Health history, n (%)		
Asthma	10 (10.6)	1 (6.7)
Hypertension	2 (2.1)	0 (0.0)
Thyroid disease	4 (4.3)	3 (20.0)
Depression	15 (16.0)	3 (20.0)
Anxiety	17 (18.1)	6 (40.0)
Current smoker	1 (1.1)	0 (0.0)

Participants completed questionnaires at enrollment, weekly thereafter for 4 weeks, and then multiple times throughout pregnancy. Medical record review was used to adjudicate adverse outcomes in a subsample of the population. We calculated the incidence and 95% confidence intervals (CIs) for EPL, defined as pregnancy loss at <20 weeks' gestation.

RESULTS: Among the 1338 PRIORITY participants, 109 were enrolled at <14 weeks gestation and comprised the analysis set; 94 had a positive test result for COVID-19 and 15 had a negative test result for COVID-19. All of the 109 patients were outpatients, and all were symptomatic. The average age of the population was 31 years; 33% of the participants were Hispanic (Table). The mean gestational age at enrollment was approximately 9 weeks; 83% of participants had at least 1 month of longitudinal follow-up before the end of pregnancy.

In the COVID-19—positive group, 6 of 94 patients (6.4%; 95% CI, 2.4%—13.4%) had EPL compared with 1 of 15 in the COVID-19—negative group (6.7%; 95% CI, 0.1%—31.9%). In the COVID-19—positive group, 5 EPLs occurred at 7 to 12 weeks' gestation and 1 occurred at 15 weeks' gestation. In a subgroup analysis of 34 COVID-19—positive participants enrolled at <8 weeks' gestation, 2 of 34 patients had EPL (5.9%). In the COVID-19—positive group, 82 of 90 patients (91.1%; 95% CI, 83.2%—96.1%) had live births, of which 82.9% (95% CI, 73%—90.3%) were at term and 17.1% (95% CI 9.7%—27%) were at <37 weeks' gestation; 4 of 94 pregnancies are ongoing but all are at >24 weeks' gestation.

CONCLUSION: In this nationwide study of pregnant people in the United States, the risk for pregnancy loss at <20 weeks' gestation was about 6% for both the participants with COVID-19 (n=94) and the controls without COVID-19 (n=15). These data compare favorably with the 10% rate of miscarriage among clinically recognized first-trimester pregnancies before the pandemic.⁶ This study conducted analyses of COVID-19 in 109 pregnant people in the first trimester in a longitudinal US cohort. With this sample size, the upper bound of the CI for pregnancy loss of 13.4% is reassuring because it is not significantly higher than the expected miscarriage rate without viral infection. These results can guide counseling for people infected with SARS-CoV-2 early in pregnancy.

Vanessa L. Jacoby, MD, MAS Amy Murtha, MD Department of Obstetrics, Gynecology, and Reproductive Sciences University of California San Francisco Box 1793, 2356 Sutter St. San Francisco, CA 94115 Vanessa.Jacoby@ucsf.edu

Yalda Afshar, MD, PhD Department of Obstetrics and Gynecology University of California, Los Angeles Los Angeles, CA

Stephanie L. Gaw, MD, PhD Department of Obstetrics, Gynecology and Reproductive Sciences University of California, San Francisco San Francisco, CA

Ifeyinwa Asiodu, PhD, RN Department of Family Health Care Nursing University of California, San Francisco San Francisco, CA

Jorge Tolosa, MD Department of Obstetrics and Gynecology Oregon Health & Science University Portland, OR

Mary E. Norton, MD Department of Obstetrics, Gynecology and Reproductive Sciences University of California, San Francisco San Francisco, CA

W. John Boscardin, PhD Department of Medicine University of California, San Francisco San Francisco, CA

Valerie Flaherman, MD, MAS Department of Pediatrics University of California, San Francisco San Francisco, CA

The authors report no conflict of interest.

This study was funded by grants from the California Healthcare Foundation, the Centers for Disease Control and Prevention Foundation, the Bill and Melinda Gates Foundation, the University of California, San Francisco's National Center of Excellence in Women's Health, Yellow Chair Foundation, and private donors. The funders had no involvement in the collection, analysis, and interpretation of data.

REFERENCES

1. Rasti S, Ghasemi FS, Abdoli A, Piroozmand A, Mousavi SG, Fakhrie-Kashan Z. ToRCH "coinfections" are associated with increased risk of abortion in pregnant women. Congenit Anom (Kyoto) 2016;56:73–8.

2. Cosma S, Carosso AR, Cusato J, et al. Coronavirus disease 2019 and first-trimester spontaneous abortion: a case-control study of 225 pregnant patients. Am J Obstet Gynecol 2021;224:391.e1–7.

3. Juan J, Gil MM, Rong Z, Zhang Y, Yang H, Poon LC. Effects of coronavirus disease 2019 (COVID-19) on maternal, perinatal and neonatal outcome: systematic review. Ultrasound Obstet Gynecol 2020;56:15–27.

4. la Cour Freiesleben N, Egerup P, Hviid KVR, et al. SARS-CoV-2 in first trimester pregnancy: a cohort study. Hum Reprod 2021;36:40–7.

5. Yan J, Guo J, Fan C, et al. Coronavirus disease 2019 in pregnant women: a report based on 116 cases. Am J Obstet Gynecol 2020;223: 111.e1–14.

6. Magnus MC, Wilcox AJ, Morken NH, Weinberg CR, Håberg SE. Role of maternal age and pregnancy history in risk of miscarriage: prospective register based study. BMJ 2019;364:1869.

© 2021 Elsevier Inc. All rights reserved. https://doi.org/10.1016/j.ajog. 2021.06.080